Trinity Capital Inc. Provides $35 Million in Growth Capital to Monteris Medical to Support Neurosurgical Technology Advancements
Trinity Capital (Nasdaq: TRIN) committed $35 million in growth capital to Monteris Medical to support commercialization of the NeuroBlate System and expansion of clinical research programs.
Rhea-AI Summary
Trinity Capital (Nasdaq: TRIN) committed $35 million in growth capital to Monteris Medical to support commercialization of the NeuroBlate System and expansion of clinical research programs. The NeuroBlate System is an MRI-guided, robotically controlled laser interstitial thermal therapy platform for brain tumors, radiation necrosis, and drug-resistant epilepsy.
The financing complements Monteris' Series E equity support and is intended to accelerate commercial expansion, product innovation, and clinical adoption at neuroscience centers.
Positive
- $35 million growth capital commitment to Monteris Medical
- Financing aimed to support commercialization of the NeuroBlate System
- Capital to expand clinical research programs and commercial footprint
Negative
- Transaction terms not disclosed beyond the $35 million commitment
- No financial return timeline or expected impact on Trinity results provided
Details
News Market Reaction – TRIN
On Mar 12, the day this news came out, TRIN closed 0.74% below the previous close.
Data tracked by StockTitan Argus for the Mar 12 session.
Key Figures
- Growth capital
- $35 million
- Commitment to Monteris Medical to support commercialization and research
Historical Context
-
$35M growth capital commitment to Neuros Medical to support commercialization.
-
$50M growth capital facility for Dwelly’s UK property-management expansion.
-
Record 2025 investment income, NII, NAV growth, and AUM expansion.
-
Preliminary Q4 and 2025 NII and NAV estimates with low non-accrual levels.
-
£25M growth capital commitment to Motorway for UK expansion.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
laser interstitial thermal therapy (litt) medical
credit facility financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Monteris Medical develops and commercializes the NeuroBlate System, a robotically controlled laser interstitial thermal therapy (LITT) platform that uses MRI-guided laser technology to remove abnormal brain tissue. The system features robotic-controlled, precise, laser energy delivery that is used to treat brain tumors, radiation necrosis, and drug-resistant epilepsy. The NeuroBlate system is designed to provide a minimally invasive alternative to traditional open neurosurgery, with the goal of helping patients experience lower complication rates and shorter hospital stays.
"We believe Monteris is advancing innovation across the life sciences sector with technology that is expanding treatment options in neurosurgery," said Rob Lake, Senior Managing Director, Life Sciences at Trinity Capital. "We are proud to support a team that is not only pushing the boundaries of medical technology, but also delivering meaningful new treatment options for patients."
The growth capital will help support Monteris Medical's commercialization of the Neuroblate System and expansion of clinical research programs.
"Securing this new credit facility from Trinity Capital, alongside the support of our Series E equity investors, strengthens our ability to accelerate growth and continue delivering innovative, minimally invasive neurosurgical solutions for patients in need," said Martin J. Emerson, President and CEO of Monteris Medical. "Trinity's partnership reflects strong confidence in our strategy, the NeuroBlate System, and the expanding clinical impact our technology is making across leading neuroscience centers. This financing ensures we can further invest in commercial expansion, product innovation, and the teams who bring our mission to life every day."
About Trinity Capital Inc.
Trinity Capital Inc. (Nasdaq: TRIN) is an international alternative asset manager that seeks to deliver consistent returns for investors through access to private credit markets. Trinity Capital sources and structures investments in well-capitalized growth-oriented companies across five distinct lending verticals: Sponsor Finance, Equipment Finance, Tech Lending, Asset Based Lending, and Life Sciences. As a long-term, trusted partner for innovative companies seeking tailored debt solutions, Trinity Capital has deployed more than
About Monteris and the NeuroBlate® System
Monteris Medical develops and markets innovative, MR‑guided laser ablation systems that enable minimally invasive, robotically controlled brain surgery, often referred to as laser ablation, LITT (laser interstitial thermal therapy) or SLA (stereotactic laser ablation). The company's NeuroBlate System is designed for adults and children aged two and older and uses laser technology to precisely destroy abnormal brain tissue, including certain brain tumors and specific areas of the brain that cause seizures due to epilepsy. NeuroBlate is the only LITT platform with a robotic interface that supports the targeted, safe delivery of laser energy and is supported by published prospective clinical data. Multicenter studies on NeuroBlate show that patients typically experience short hospital stays, low rates of complications, improved quality of life and outcomes comparable to open surgical resection.
View original content to download multimedia:https://www.prnewswire.com/news-releases/trinity-capital-inc-provides-35-million-in-growth-capital-to-monteris-medical-to-support-neurosurgical-technology-advancements-302711455.html
SOURCE Trinity Capital Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.